BRAINSTORM CELL THERAPEUTICS INC. Brainstorm Cell Therapeutics Inc. Stock Deutsche Boerse AG
Equities
GHDN
US10501E2019
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.356 EUR | +3.34% |
|
-1.79% | +54.78% |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 27.46M 25.67M 37.51M |
|---|---|---|---|---|---|
| Net income 2024 * | -21M -19.63M -28.68M | Net income 2025 * | -24M -22.43M -32.78M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.4
x | P/E ratio 2025 * |
-1.63
x | Employees | 29 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 86.62% |
More Fundamentals
* Assessed data
More news
Latest transcript on Brainstorm Cell Therapeutics Inc.
More press releases
| 1 day | +3.34% | ||
| 1 week | -1.79% | ||
| Current month | -25.05% | ||
| 1 month | -26.67% | ||
| 3 months | -39.66% | ||
| 6 months | +82.56% | ||
| Current year | +54.78% |
1 week
0.34
0.38
1 month
0.340.50
Current year
0.240.80
1 year
0.111.94
3 years
0.114.45
5 years
0.1114.90
10 years
0.1114.90
| Managers | Title | Age | Since |
|---|---|---|---|
Chaim Lebovits
CEO | Chief Executive Officer | 53 | 07-06-30 |
Alla Patlis
DFI | Director of Finance/CFO | 37 | 12-12-22 |
| Chief Tech/Sci/R&D Officer | - | 22-05-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Irit Arbel
FOU | Founder | 64 | 00-09-21 |
Uri Yablonka
BRD | Director/Board Member | 47 | 14-06-05 |
Jacob Frenkel
CHM | Chairman | 81 | 20-03-29 |
| Date | Price | Change |
|---|---|---|
| 24-06-26 | 0.356 | +3.34% |
| 24-06-25 | 0.3445 | +0.88% |
| 24-06-24 | 0.3415 | -2.71% |
| 24-06-21 | 0.351 | -7.02% |
| 24-06-20 | 0.3775 | +4.14% |
Delayed Quote Deutsche Boerse AG, June 26, 2024 at 02:12 am
More quotes
BrainStorm Cell Therapeutics Inc. is a developer of autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The neurodegenerative diseases include Amyotrophic Lateral Sclerosis (ALS), Progressive Multiple Sclerosis (PMS), Alzheimerâs disease (AD), and others. The Company is engaged in the clinical development and commercialization of the NurOwn technology platform used to produce autologous mesenchymal stem cells- neurotrophic factors (MSC-NTF) cells. NurOwn leverages cell culture methods to induce autologous bone marrow derived MSCs to secrete high levels of NTFs, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. Autologous MSC-NTF cells is for the treatment of ALS. It has completed a phase III trial in ALS. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd., holds exclusive rights to commercialize NurOwn technology.
Calendar
2024-08-11
- Q2 2024 Earnings Release (Projected)
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +38.36% | 52.73B | |
| +36.73% | 39B | |
| -8.63% | 38.52B | |
| +25.46% | 30.38B | |
| -11.17% | 26.39B | |
| +11.44% | 26.08B | |
| +45.09% | 14.15B | |
| +32.93% | 12.6B | |
| -5.30% | 11.51B |
- Stock Market
- Equities
- BCLI Stock
- GHDN Stock
